Preening Bulls Enjoy Time in the Sun<br />By Rev Shark<br />RealMoney.com Contributor<br />4/17/2008 8:38 AM EDT <br /><br /><br />Blaming is easy; doing better is more difficult. <br />-- German proverb<br /><br />We all know the problems that have been plaguing this market. Stories about the debt crisis, a slowing economy, a horrible housing market, a very weak dollar and accelerating food and oil prices fill the newspapers and should worry any thinking person. However, despite these negatives, the market produced a very strong rally yesterday, and many market players are ready to declare that the bear market is over. <br /><br />Is it really possible that the market could be bottoming out while many are still trying to figure out if we really are having a recession or not? The stock market is a discounting mechanism that looks forward and tries to price in events before they occur. For a while now it has been pricing all those negatives we have been hearing about. <br /><br />Unfortunately, pricing in future events is a very hard thing to do. That leads to premature rallies when market players become too hopeful, and further downside when pessimism flares back up. The market is never very precise when it comes to predicting the future, and that is what makes our job as investors so difficult. <br /><br />Yesterday the market had a very good day because earnings reports from Intel (INTC) and JPMorgan (JPM) , while mediocre, were better than many had expected. IBM (IBM) earnings last night helped reaffirm the idea that expectations were low and that the worst has already been priced in. <br /><br />So is that it? Is the worst priced in and the market ready to rally? For now it looks that way. The technical condition of the indices is improved as we move back over key levels at the 50-day moving average. The news flow is helping matters and market players are hungry to declare the bear market over and to put money to work. <br /><br />The bulls have the benefit of the doubt for now, but it would be naïve of us to assume that the market has correctly and completely priced in all our troubles and woes. It may look that way, but the likelihood is that many will overanticipate the possibility that all bad news has been foreseen and discounted. <br /><br />Already this morning, emotions have cooled a bit from what we saw immediately after the strong IBM report last night. We have a mild open, and many are looking forward to economic data and an earnings reports from Google (GOOG) . <br /><br />Even with the much better action yesterday, the two-tiered nature of the advance is of concern. There is extremely wild momentum in a few groups like fertilizers, energy and steel. Market players are chasing those groups aggressively while ignoring most of the rest of the market. We need the momentum to spread out and become less concentrated if this market is going to put in a sustained upside move. <br /><br />The market is showing promise, but we need to keep in mind that the discounting of future bad news by the market is imperfect at best; it is extremely likely that there will be more pullbacks along the way. For now, though, the market is feeling like it has been too pessimistic, and that is supporting further upside. Things can change fast as more news and earnings hit, but the bulls have the ball, and it won't take much for them to run us up a bit more. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: AVCT +17.6%, ALTR +9.4%, DTLK +8.7%, GKK +7.1%, KNL +6.7%, LEG +6.6%, CCK +6.3%, CAVM +5.7%, ATR +4.0%, FHN +3.3%, TXT +2.9%, FCS +2.6%, IBM +2.4% (also upgraded to Buy and $150 tgt at Canaccord), CHKP +2.3%, TCBI +1.6%, CY +1.6%... M&A news: IDGR +2.6% (to be acquired by WCC for $11.75/share)... Other news: ABPI +35.8% (says independent DMC recommends presenting data on BiovaxID to FDA and worldwide regulatory agencies in order to seek marketing approvals for Follicular Non-Hodgkin's Lymphoma), AVAN +28.9% (Pfizer and AVANT enter into licensing and development agreement for novel therapeutic vaccine candidate for brain cancer), SPPI +7.6% (presents data on lucanthone; preclinical data demonstrates potential applications in lung cancer therapy), ICO +5.6% (still checking), TASR +3.8% (receives follow-on overseas order for TASER cartridges), ISIS +2.8% (GSK and Regulus Therapetuics, JV between ALNY and ISIS, form strategic alliance to develop MicroRNA targeted therapeutics to treat inflammatory diseases)... Analyst upgrades: OMTR +5.3% (upgraded to Buy at Citigroup), CPHD +1.4% (upgraded to Buy at UBS), HK +1.4% (initiated with Buy at UBS).<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance: BGG -14.6%, CMOS -13.8%, EPIC -12.0%, NOK -11.0%, CNW -9.8%, PLCM -9.0%, WTS -8.4%, SFN -7.6%, CIT -4.9%, HOG -4.9%, DHR -4.8%, IGT -4.6%, SPWR -4.6%, ISIL -4.4%, PFE -3.8%, BBT -3.4%, CMA -3.0%, TBI -3.0%, GILD -2.5%, EBAY -2.2%, MER -2.2%, PNC -2.1%, LSTR -1.8%, UTX -1.5%... Other news: VPHM -5.9% (announces discontinuation of HCV-796 development), FTE -4.9% (eyes bid for TeliaSonera - Financial Times), CHINA -4.8% (says CDC Software expects total revs for Q1 of 2008 to be between US$84.6-$85.6 mln), HGSI -4.8% (reacquires GSK rights to TRAIL receptor antibodies in return for reduction in Syncria royalties), MTH -4.7% (announces public offering of common stock), ERIC -3.1% (down in sympathy with NOK), NVS -1.8% and AZN -1.5% (down in sympathy with PFE)... Analyst downgrades: BMI -4.0% (downgraded to Underperform at Baird), HGSI -4.0% (downgraded to Hold at Citigroup), USU -3.6% (initiated with Sell at Merrill), ODFL -2.4% (downgraded to Neutral at Baird), IP -1.5% (downgraded to Neutral at Credit Suisse), X -1.4% (downgraded to Hold at Citigroup), MT -1.4% (downgraded to Neutral at HSBC), PG -0.9% (downgraded to Hold at Deutsche Bank).